Perkins, Adam http://orcid.org/0000-0002-9162-0189
Patrick, Fiona
Wise, Toby http://orcid.org/0000-0002-9021-3282
Meyer, Nicholas
Mazibuko, Ndaba
Oates, Alice E.
van der Bijl, Anne H. M.
Danjou, Philippe
O’Connor, Susan M.
Doolin, Elizabeth
Wooldridge, Caroline
Rathjen, Deborah
Macare, Christine
Williams, Steven C. R. http://orcid.org/0000-0003-4299-1941
Young, Allan H. http://orcid.org/0000-0003-2291-6952
Funding for this research was provided by:
Bionomics Ltd
Article History
Received: 9 June 2020
Revised: 14 November 2020
Accepted: 27 November 2020
First Online: 5 January 2021
Conflict of interest
: A.H.Y. and S.C.R.W. are members of the Bionomics Scientific Advisory Board. S.M.O’C. and E.D. are employed by Bionomics Ltd. All other authors report no biomedical financial interests or potential conflicts of interest. EU Clinical Trials Register: A Randomized, Double-Blinded, Placebo and Lorazepam-Controlled, Four-Way Crossover, Phase II Study to Evaluate the Effects of Single Oral Administration of BNC210 on Brain Activity Changes Captured by Functional Magnetic Resonance Imaging in Adults With Generalized Anxiety Disorder; trial/2014-004937-15/GB; BNC210.006.